LENZLENZ Therapeutics Inc.
LENZ
LENZ Therapeutics Inc.1,275
Mkt Cap
$313.23MVolume
32,349.0052W High
$50.4052W Low
$8.25PE Ratio
-3.56LENZ Fundamentals
Price
$9.99Prev Close
$10.06Open
$10.0850D MA
$10.26Beta
1.50Avg. Volume
728,695.69EPS (Annual)
-$2.85P/B
1.10Rev/Employee
$125,578.95$169.48
Compact View
Not available
Not available
Poll
Earnings Recap
• Reported GAAP EPS of -$1.32 down -149.06% YoY • Reported revenue of $1.9M • LENZ Therapeutics believes its existing cash, cash equivalents, and marketable securities of $258.4M as of March 31, 2026, are sufficient to fund operations for at least the next 12 months and reach positive operating cash flow.
Bullish
LENZ Therapeutics achieved FDA approval for VIZZ, its sole product, in July 2025, backed by robust patent protection until at least 2044 and strategic international licensing agreements.
Bearish
LENZ Therapeutics faces ongoing net losses and significant competition for VIZZ, alongside substantial reliance on third-party manufacturing and potential market acceptance challenges for its sole product.